Introduction
While a well balanced vaginal microbiome is known to prevent vulvo-vaginal infections, recent evidence suggests that the state of the vaginal microbiome could influence the development of cancer. Previous research on the gastrointestinal microbiome has shown that commensal bacteria can promote or inhibit carcinogenesis. Although gastrointestinal bacteria play significant roles in aiding digestive processes and maintaining a healthy immune system, disruption of the microbiome can allow certain opportunistic species to become pathogenic and contribute to the development of disease. Studies have also associated the microbiome and inflammatory bowel disease, as well as the pertinence of the microbiome beyond the gastrointestinal system. 1, 2 More recent analysis has identified potential links between the microbiome and gynaecological cancers. 3 Although smaller in population, the vaginal microbiome may have similar effects on immune regulation and oncogenesis. Here, we review the role of the human microbiome in cancers, focusing specifically on the vaginal microbiome.
Recent studies have indicated that changes in the vaginal microbiome could affect the risk of gynaecological cancers. A healthy vaginal microbiome dominated by Lactobacillus species may have a protective effect and therapeutic potential.
The gut microbiome and cancer
Of the 500-1000 different species of gut bacteria in any individual human, several are known to affect carcinogenesis. 4 Helicobacter pylori has been linked to gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma due to its ability to induce chronic inflammation leading to malignant transformation of B cells.
5 Antibiotic treatment to eradicate the H. pylori infection is often sufficient to treat localised gastric MALT lymphoma. 6 Similarly, immunoproliferative small intestinal disease (IPSID) lymphoma has been successfully treated by antibiotic elimination of Campylobacter jejuni infection. 7 Fusobacterium and Providencia have been associated with the colon cancer microbiome, which also has increased diversity compared with healthy colon tissue. 8, 9 Chronic inflammation at the site of tumorigenesis appears to be the main mechanism by which specific bacterial species contribute to the development of cancer. For example, Streptococcus bovis is involved in the pathogenesis of colonic neoplasia 10 via chronic inflammation by the innate immune system. 11 Similarly, inflammation from chronic Salmonella enterica typhi infection has been associated with gallbladder cancer. 12 In particular, Th17 pathways have been identified to play a role in tumorigenesis, and are known to be induced by Helicobacter. 13 Mouse models have linked additional species with cancer and have shown that the rate of cancer growth can be increased or decreased in germ-free or antibiotic-treated mice.
14 Another mouse study showed that the composition of the microbiome directly impacts tumorigenesis and progression. 15 Although many studies have highlighted the role of gut microflora in carcinogenesis, several other investigations suggest that some bacteria may have a protective role against development of certain cancers. Paradoxically, H. pylori was associated with a reduction in the risk of oesophageal adenocarcinoma, 16 oesophageal squamous cell carcinoma, 17 and pancreatic cancer 16 in East Asian populations. Lactobacillus species were found to improve survival in a colorectal cancer mouse model and reduce postoperative complications in colorectal cancer surgery clinical trials. 18 Such protection may result from activation of the immune system against cancer cells, specifically anti-inflammatory Treg cells 13 and Th17 and innate immune pathways. Maintaining a normal set of microflora has been found to be essential for these pathways. 19, 20 Increased rates of multiple cancer types in mice devoid of microflora 14 also supports this assertion. Other protective mechanisms of bacteria against cancer include triggering of apoptosis in cancer cells, antioxidant scavenging of free radicals, and induction of tumour suppressor genes. 18 This bacterial activation of the immune system may improve immune surveillance of cancer and lead to decreased risk of disease. 21 The effects of gastrointestinal bacteria are not limited to cancers within the digestive tract. The intestinal microbiome has also been shown to propagate hepatocellular carcinoma, 1 possibly through the translocation of bacterial components such as lipopolysaccharides to the liver, indirectly via systemic inflammation, or through innate immune pathways via TLR4. 1 Chronic infection of S. enterica typhi in the gastrointestinal tract has been associated with pancreatic and lung cancer. 2 More broadly, the gut microbiota appears to have systemic effects on the immune system. 22 Several studies have reported systemic Th17 inflammation or anti-inflammatory Treg activation due to the presence of commensal microbes of the gut. 23, 24 Such systemic effects could alter the risk of cancer in any organ, 25 including the cervix, ovaries and uterus.
The vaginal microbiome
The vaginal microbiome comprises a diverse array of bacterial species, usually between 20 and 140 in any particular individual, with marked variation between individuals and over time. 26, 27 Vaginal microbiomes can be classified according to the most dominant species of bacteria present, which is most commonly a species of Lactobacillus. 28 Lactobacillus crispatus and Lactobacillus iners were dominant in two of the most common types of microbiome, and Lactobacillus gasseri and Lactobacillus jensenii were occasionally dominant as well. In these Lactobacillus-dominated microbiomes, the pH was typically <4.5. Such a pH is well tolerated by Lactobacillus, but inhibitory to several other types of bacteria. Microbiomes identified with significantly higher pH were not dominated by Lactobacillus but instead were characterised by high bacterial diversity and a prevalence of anaerobic species. A follow-up study showed similar microbiome types with two additional groups dominated by Gardnerella vaginalis subtype A or subtype C. 29 These microbiome types are fairly stable but can fluctuate occasionally. 30 Like the gut microbiome, alteration of the vaginal flora could play a part in the pathogenesis of several diseases by modulating immunity or increasing the growth of pathogenic strains. 31 Perhaps the most important role of a healthy microbiome is in preventing vaginal infections and inflammatory conditions. If the vaginal microbiome becomes disrupted by antibiotics or other factors, there is an increased incidence of bacterial vaginosis or candidal vulvovaginitis. 32 As in the gut microbiome, higher diversity in the vaginal microbiome is correlated with increased incidence of inflammatory conditions, in this case candidal vulvovaginitis or bacterial vaginosis. 33 In bacterial vaginosis, there is a reduction in Lactobacillus and an increase in the abundance of other bacteria such as Prevotella. 34 Once the bacterial vaginosis is treated with antibiotics, the vaginal microbiome becomes less diverse, with increasing frequency of lactobacilli. 35 The composition of the vaginal microbiome has implications for other infectious diseases as well. In one study, cervicitis was associated with Mageeibacillus indolicus, and individuals without cervicitis had a greater abundance of L. jensenii.
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Microbiomes with abundant lactobacilli appear to reduce the risk of HIV transmission. 37 It has also been suggested that a vaginal microbiome plays a role in preterm birth 38 and that a vaginal microbiome rich in lactobacilli reduces its incidence. 39, 40 Overall, Lactobacillus species appear to be protective, and disturbance in the vaginal microbiome appears to be a factor in the pathogenesis of several diseases, impacting immune regulation and inflammation. This type of disturbance may also promote carcinogenesis.
Influence of vaginal microbiome on carcinogenesis
Research on the relation between the vaginal microbiome and gynaecological cancers is still in its infancy. Nevertheless, results from several recent studies have suggested a potential link. The most clear effect is how the microbiome mediates the risk of human papillomavirus (HPV)-induced cervical cancer. It is well known that certain strains of HPV significantly increase the risk of cervical cancer. 41, 42 One study showed that women who have been infected with HPV had microbiomes with greater bacterial diversity, 43 specifically abundant in L. gasseri and G. vaginalis. A twin study found higher rates of HPV in individuals with lower levels of Lactobacillus and greater vaginal microbiome diversity. 44 Fusobacteria, including Sneathia, are most strongly correlated with HPV infection. The rate of clearance of HPV, and thus the risk of developing HPV-associated malignant transformation, may also be dependent on the composition of the microbiome. 45 Specifically, vaginal microbiomes with greater amounts of L. gasseri or L. iners were associated with rapid remission of HPV, whereas microbiomes with low amounts of Lactobacillus and high amounts of Atopobium were associated with slower HPV clearance. It is interesting to note that although L. gasseri was positively correlated with a higher level of HPV infection, 43 it was also associated with a higher remission rate. 45 It has been suggested that vaginal infection by Chlamydia trachomatis may also predispose individuals to HPV infection by altering the microbiome. 46 However, it appears that the vaginal microbiome can be directly correlated to gynaecological cancers as well. A handful of studies have examined the association between the vaginal microbiome and cervical intraepithelial neoplasia (CIN) (see Table 1 ). In general, microbiomes rich in L. crispatus were associated with healthy patients. [47] [48] [49] Lactobacillus iners, on the other hand, was associated with cervical cancer alone 48 or in conjunction with HPV infection, 47 as well as higher grades of CIN in HPV-positive patients. 50 Conversely, another study found that L. iners was associated with reduced risk of squamous intraepithelial lesions and cervical cancer. 49 Other species of Lactobacillus were also variably associated with CIN. 50, 51 A diverse array of less abundant bacterial species were associated with CIN, including Atopobium vaginae, 47,48 G. vaginalis, 47 Fusobacterium 49 and others. 51 Cytokine profiling revealed higher local levels of interleukin (IL)-4 and transforming growth factor (TGF)-b1 mRNAs in microbiomes dominated by Fusobacterium. 49 Cytokine profiling revealed higher local levels of IL-4 and TGF-b1 mRNAs in microbiomes dominated by Fusobacterium. 49 Similarly, patients with squamous intraepithelial lesions tended to have microbiomes enriched in Sneathia. 49 Diet could potentially affect the microbiome, and it was found that women with semi-Western-style diets as opposed to a diet rich in fish and vegetables had a higher rate of CIN. 48 In addition to its effects on cervical cancer, the microbiome may impact the risk of cancer by other mechanisms as well, such as prevention of chronic infection associated with cervical neoplasia. 52 Although the pathogenesis of endometrial cancer most commonly involves oestrogen excess, there is also a demonstrated link between pelvic inflammatory disease and endometrial cancer. 53 The vaginal microbiome and bacterial vaginosis are linked to pelvic inflammatory disease. 54, 55 Thus, disruption of the microbiome may be a risk factor indirectly for endometrial cancer. The risk of ovarian cancer may be similarly modulated by indirect effects of the vaginal microbiome, via regional inflammation or modulation of local immunosurveillance. A recent study suggests that ovaries and fallopian tubes possess unique microbiomes, and there may be differences in the composition of these upper genital tract microbiomes in patients with epithelial ovarian cancer compared with cancer-free controls. 56 A new study also found a correlation between the uterine microbiome composition and endometrial cancer. 57 In particular, A. vaginae and a Porphyromonas species were associated with cancer.
Clinical considerations
The growing importance of the microbiome in cancer and other diseases 58 encourages potential therapy that reinstates or maintains healthy microbiota. 59 Probiotics can maintain or reform a healthy balance of bacterial species. Oral probiotics have been effective at treating several gastrointestinal diseases, including traveller's diarrhoea, gastroenteritis, inflammatory bowel disease, irritable bowel syndrome, and others. 60 They can even reduce the relapse rate of bacterial vaginosis. 61 Various formulations of probiotics have been studied but generally consist of an oral dose of Lactobacillus and Bifidobacterium species in concentrations of at least 5 9 10 9 colony forming units per day for at least 5 days. 60 Oral probiotics have been used successfully as adjunct treatments for cancer patients. Taken simultaneously with the primary therapy, they were able to replace microflora depleted by antibiotics 60 or radiation therapy, 3 and have been used as preventative measures in some cases. 62 Vaginal probiotics may be useful for this purpose, and even oral probiotics can help preserve normal vaginal flora during antibiotic therapy. 63 Direct vaginal probiotics including Lactobacillus species have also been successfully utilised in several interventions, 64 including reduction of bacterial vaginosis. 65 It has also been suggested that use of vaginal probiotics for preventing bacterial vaginosis may be able to decrease the risk of preterm birth. 39, 40 Probiotics could also have more direct effects on carcinogenesis and treatment. It has been suggested that regular intake of oral probiotics may decrease the risk of gastrointestinal cancer. 66 Vaginal probiotics could work similarly, particularly by reducing the rate of HPV infection and increasing the rate of HPV clearance. Additionally, the microbiome may play a role in treatment by modulating the tumour microenvironment. 67 One study showed that CpG oligonucleotide immunotherapy or platinum chemotherapy regimens had superior effectiveness against tumours in mice with normal gut microbiomes compared with mice raised in germ-free environments or to mice treated with antibiotics. 68 In another study, the presence of Bacteroides thetaiotaomicron or Bacteroides fragilis was necessary for the success of immunotherapy targeting CTLA-4 in both humans and mice. 20 This type of immunotherapy is also under investigation as a treatment for gynaecological cancers, 69 and the vaginal microbiome could similarly influence its effectiveness. Probiotics alone have been shown to be sufficient to prevent sarcomas in mice by reducing the level of gut Th17 inflammation and promoting anti-inflammatory Treg cells. 20, 70 Vaginal probiotics, such as gut probiotics for gastrointestinal cancers, could potentially reduce the risk of gynaecological cancers by similar mechanisms, such as promotion of immune surveillance and promotion of Treg cells to reduce chronic inflammation. A probiotic could also be applied directly to or injected into a gynaecological tumour, where it could favourably alter the tumour microenvironment. Indeed, in vitro studies have already indicated that vaginal microflora could enhance apoptosis of cancer cells 71, 72 or induce dendritic cells and Treg cells to produce anti-inflammatory cytokines. 73 
Conclusions and future directions
Most recent studies indicate that the microbiome plays an important part in carcinogenesis. Although several species from the gastrointestinal tract have been linked to carcinogenesis via immune dysregulation, mouse models have also shown that normal gut microflora are critical for inhibiting carcinogenesis. Such a well balanced microbiome may reduce inflammation via Treg cells and provide an optimal level of immune activation for anticancer immunosurveillance. The vaginal microbiome, in addition to its role in common conditions such as vaginitis and HPV infection, may also have an impact on the development or prevention of gynaecological cancers (Figure 1 ). Additional research is needed to determine if and when modulation of the vaginal microbiome via probiotics could be used as a preventive strategy or contribute to the treatment of gynaecological cancers. Future epidemiological studies should also further assess the microbiome as a risk factor for disease, 74 including cancers. While previous studies have focused on the vaginal and cervical microbiome, it may be useful to investigate the perinatal, 75 uterine, 76 and ovarian 56 microbiomes as well. Consideration of fungal species 34 in such studies may also yield interesting results. Future microbiome research into inflammation and carcinogenesis certainly promises to provide unique and interesting insights into health and disease.
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